NIDA CRADA with Reckitt & Colman Pharmaceuticals
The National Institute on Drug Abuse is contemplating a CRADA with Richmond, Va.-based Reckitt & Colman Pharmaceuticals to license sublingual dosage forms of buprenorphine -- in combination with naloxone or alone -- for the treatment of opiate dependence, May 12 Federal Register notice states. Reckitt & Colman markets the opioid analgesic Buprenex (buprenorphine) injectable for the relief of moderate to severe pain.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth